Viking Therapeutics Q3 net loss more than doubles to $183.19 million

By Public Technologies20:12 (UTC), 28 October 2026 Updated

Viking Therapeutics’ third-quarter 2026 net loss more than doubled year over year to $183.19 million due to higher operating expenses.
Research and development expenses jumped 85% to $166.8 million, primarily due to increased clinical study and manufacturing costs.
Quarter-end cash, cash equivalents and short-term investments totaled $960 million, including approximately $550 million in net financing proceeds.
Oral VK2735 Phase 3 SUNRISE trials began; subcutaneous VK2735 Phase 3 VANQUISH studies remain on track for completion in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610281605PR_NEWS_USPR_____LA83746) on October 28, 2026, and is solely responsible for the information contained therein.